Related Experiment Video
Updated: Apr 20, 2026
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
KCa3.1: a new player in progressive kidney disease
Chunling Huang1, Carol A Pollock, Xin-Ming Chen
1Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Insights
Targeting KCa3.1 shows promise in reducing diabetic nephropathy progression. Further human studies are needed to explore KCa3.1 blockade for treating established kidney disease.
Area of Science:
- Nephrology
- Cardiovascular Research
- Molecular Biology
Background:
- Hypertension and hyperglycemia are primary drivers of chronic kidney disease (CKD).
- Current treatments targeting blood pressure and glucose, along with renin-angiotensin-aldosterone system blockade, slow CKD progression but are not universally effective.
- Novel therapeutic strategies are required to halt or reverse CKD pathology.
Purpose of the Study:
- To review the therapeutic potential of targeting KCa3.1 in the context of chronic kidney disease (CKD).
- To discuss the role of KCa3.1 in the pathological processes of CKD, particularly diabetic nephropathy.
Main Methods:
- Review of preclinical studies investigating KCa3.1 inhibition in animal models of diabetic nephropathy.
- Analysis of cellular mechanisms involving KCa3.1 in renal fibroblasts and proximal tubular cells.
- Examination of KCa3.1's role in vascular smooth muscle cell function under diabetic conditions.
Main Results:
- KCa3.1 blockade inhibits renal fibroblast activation and the TGF-β1/SMAD pathway in diabetic mice.
- Reduced nuclear factor-κB activation observed in human proximal tubular cells under diabetic conditions with KCa3.1 blockade.
- Advanced glycosylated endproducts upregulate KCa3.1, promoting vascular smooth muscle cell migration and proliferation via Ca²⁺-dependent pathways.
Conclusions:
- Despite optimal control of hypertension and hyperglycemia, many CKD patients progress to end-stage disease, necessitating new therapeutic targets.
- Genetic deletion or pharmacologic inhibition of KCa3.1 significantly mitigates diabetic nephropathy development in animal models.
- Further investigation is crucial to determine the efficacy of KCa3.1 blockade in preventing and treating established diabetic nephropathy in humans.
Purpose Of Review:
Hypertension and hyperglycaemia are major risk factors that result in chronic kidney disease (CKD). Achievement of blood pressure goals, optimal control of blood glucose levels and the use of agents to block the renin-angiotensin-aldosterone system slow the progression of CKD. However, not all patients are benefited by these interventions and novel strategies to arrest or reverse the pathological processes inherent in CKD are needed. The therapeutic potential of targeting KCa3.1 in CKD will be discussed in this review.
Recent Findings:
Blockade of KCa3.1 ameliorates activation of renal fibroblasts in diabetic mice by inhibiting the transforming growth factor-β1/small mothers against decapentaplegic pathway. A concomitant reduction in nuclear factor-κB activation in human proximal tubular cells under diabetic conditions has been observed. Advanced glycosylated endproducts induce both protein expression and current density of KCa3.1, which, in turn, mediates migration and proliferation of vascular smooth muscle cells via Ca²⁺-dependent signalling pathways.
Summary:
Studies have clearly demonstrated a causal role of chronic hyperglycaemia and hypertension in the development of CKD. However, a large proportion of patients develop end-stage kidney disease despite strict glycaemic control and the attainment of recommended blood pressure goals. Therefore, it is essential to identify and validate novel targets to reduce the development and progression of CKD. Recent findings demonstrate that genetic deletion or pharmacologic inhibition of KCa3.1 significantly reduces the development of diabetic nephropathy in animal models. However, the consequences of blockade of KCa3.1 in preventing and treating established diabetic nephropathy in humans warrants further study.
More Related Videos
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:25Chronic Kidney Disease I: Introduction
01:24Chronic Kidney Disease II: Clinical Manifestations
01:29Acute Kidney Injury III: Clinical Manifestations
01:22Acute Kidney Injury I: Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention